182274-80-2

Upstream product

• 6278-73-5 2-(4-aminophenyl)benzothiazole 
• 79-04-9 chloroacetyl chloride 
• 137-07-5 2-amino-benzenethiol 
• 20934-81-0 4-(benzo[d]oxazol-2-yl)aniline 
• 122-04-3 4-nitro-benzoyl chloride 
• 1843-21-6 N-phenyl-2-benzothiazolamine 
• 22868-34-4 2-(4-nitrophenyl)benzothiazole 
• 150-13-0 4-amino-benzoic acid 

Downstream Products

• 911103-51-0 {[(4-benzothiazol-2-yl-phenylcarbamoyl)-methyl]-pyridin-2-ylmethyl-amino}-acetic acid ethyl ester 
• 1156005-43-4 N-{[4-(1,3-benzothiazol-2-yl)anilino]carbonylmethyl}iminodiacetic acid 
• 1388658-07-8 N-(4-benzothiazol-2-ylphenyl)-2-[3-(methoxyphenyl)sulfanyl]acetamide 
• 1388657-72-4 N-(4-benzothiazol-2-yl-phenyl)-2-(3-cyanophenoxy)acetamide 
• 1426262-59-0 C₂₈H₃₂N₄O₂S₂ 
• 1426262-61-4 C₂₈H₃₄N₄OS₂ 
• 1426925-72-5 tert-butyl 2,2′,2″-(10-(2-(4-(benzo[d]thiazol-2-yl)phenylamino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 

Relevant academic research and scientific papers

Hit to lead optimization of a series of N-[4-(1,3-benzothiazol-2-yl)phenyl]acetamides as monoacylglycerol lipase inhibitors with potential anticancer activity

A total of thirty five new N-[4-(1,3-benzothiazol-2-yl)phenyl]acetamide derivatives were synthesized and structures of all the compounds were confirmed on the basis of elemental analysis and collective use of IR, 1H NMR, 13C NMR and

Evaluation of Re and 99mTc complexes of 2-(4′-aminophenyl) benzothiazole as potential breast cancer radiopharmaceuticals

The synthesis of M(I)(CO)3(NNO) (M = Re, 99mTc) complexes conjugated to the antitumor agent 2-(4′-aminophenyl) benzothiazole and to its 6-methyl derivative, as well as their in vitro and in vivo biological evaluation as breast cancer radiopharmaceuticals, is reported. The Re complexes displayed under the fluorescence microscope clear uptake by the sensitive to the 2-(4′-aminophenyl)benzothiazole pharmacophore breast cancer cell lines MCF-7 and T47D, while uptake by less sensitive lines and by normal fibroblasts was much weaker. In accordance, uptake of the corresponding radioactive 99mTc complexes was clearly higher in the breast cancer cell lines MCF-7 and MDA-231 compared to normal fibroblasts. Biodistribution of the 99mTc complexes in SCID mice bearing MCF-7 xenografts showed appreciable tumor uptake. A tumor/muscle ratio of 2.2 was measured for the complex conjugated to 2-(4′-aminophenyl)benzothiazole that led to successful tumor imaging. The results render the 2-(4′-aminophenyl) benzothiazole complexes potential candidates for imaging (99mTc) and targeted radiotherapy (188Re) of breast cancer.

Synthesis and antitumor activity evaluation of new 2-(4-aminophenyl)benzothiazole derivatives bearing different heterocyclic rings

Twenty-five new N-[4-(benzothiazole-2-yl)phenyl]acetamide derivatives bearing different heterocyclic ring systems were synthesized using 2-(4-aminophenyl)benzothiazole structure as a pharmacophoric group. Final compounds were screened for their potential

Design, Synthesis, and Biological Evaluation of 2-(4-Aminophenyl)benzothiazole Analogues as Antiproliferative Agents

A series of 28 novel 2-(4-aminophenyl)benzothiazole analogues have been synthesized and characterized using various analytical techniques like 1H NMR, 13C NMR, electrospray ionization mass spectrometry, and IR and bioevaluated for their antiproliferative activity over a group of three human cancer cell lines, namely, lung cancer (A549), cervical cancer (HeLa), and breast cancer (MDA-MB-231), using sulforhodamine B assay method. Few synthesized molecules (5a, 5c, 5d, 5f, 7b, and 7j) displayed effective growth inhibition (GI50) activity against the tested human cancer cell lines at lower micromolar concentration (GI50) values in the range 0.2–1.7?μM. Noticeably, compound 7b exhibited reasonable activity in all three cancer cell lines in the GI50 range 0.55–1.2?μM. Further, when 7b was screened for tubulin polymerization inhibition, it exhibited more than 55% inhibition at concentration of 5.0?μM. The molecular docking simulations supported the molecular interactions of the derivatives with the targeted receptor. These derivatives may serve as lead structures for development of potential anticancer drug candidates, and 7b might act as a potential microtubule polymerization inhibitor.

4 - (Benzothiazol -2 - yl) - N -substituted aniline compound as well as preparation method and application thereof

The invention provides 4 - (benzothiazol -2 - yl) - N - substituted aniline compound and a preparation method thereof, wherein the method comprises the following steps: replacing 4 - (benzothiazol -2 - yl) aniline and a halogenated compound to generate 4

Small molecule inhibition of microRNA-21 expression reduces cell viability and microtumor formation

MicroRNAs (miRNAs) are short, non-coding RNA molecules estimated to regulate expression of a large number of protein-coding genes and are implicated in a variety of biological processes such as development, differentiation, proliferation, and cell surviva

Design and synthesis of three series of novel antitumor–azo derivatives

Three new series of thiazoles, quinolones, and thiazolidinones merged with benzimidazole, benzoxazole, and benzothiazole nuclei were synthesized. The compounds were subjected to Infrared, 1H nuclear magnetic resonance, 13C nuclear ma

Synthesis, conjugation and relaxation studies of gadolinium(iii)-4- benzothiazol-2-yl-phenylamine as a potential brain specific MR contrast agent

Magnetic resonance (MR) imaging is widely used in clinical research to map the structural and functional organization of the brain. We have designed and synthesized a Gd-based specific MR contrast agent that binds to regions in the brain. The presented co

Design, synthesis and structure-activity relationship of rhenium 2-arylbenzothiazoles as β-amyloid plaque binding agents

To continue our efforts toward the development of 99mTc PiB analogs, we have synthesized 24 neutral and lipophilic Re (as a surrogate of 99mTc) 2-arylbenzothiazoles, and explored their structure-activity relationship for binding to Aβ1-40 fibrils. These Re complexes were designed and synthesized via the integrated approach, so their 99mTc analogs would have a greater chance of crossing the blood-brain barrier. While the lipophilicities (log PC18 = 1.59-3.53) of these Re 2-arylbenzothiazoles were all within suitable range, their binding affinities (Ki = 30-617 nM) to Aβ1-40 fibrils varied widely depending on the selection and integration of the tetradentate chelator into the 2-phenylbenzothiazole pharmacophore. For potential clinical applications, further refinement to obtain Re 2-arylbenzothiazoles with better binding affinities (99mTc analogs for more widespread application via the use of SPECT scanners.

Synthesis, characterization and coordination chemistry of aminophenylbenzothiazole substituted 1,4,7-triazacyclononane macrocycles

The synthesis and spectroscopic characterization of four new 2-(4-aminophenyl)benzothiazole substituted 1,4,7-triazacyclononane derivatives with and without appended pyridyl groups on the macrocycle is reported: 1-(2-(4-aminophenyl)benzothiazolyl)-2-oxoethyl)-1,4,7-triazacyclononane (L1), 1-(2-(4-aminophenyl)benzothiazolyl)-2-oxoethyl)-4-(2-pyridylmethyl)-1,4, 7-triazacyclononane (L2), 1-(2-(4-N-methylaminophenyl)benzothiazolyl)-2- oxoethyl)-4-(2-pyridylmethyl)-1,4,7-triazacyclononane (L3), 1,4-bis(2- pyridylmethyl)-7-(2-(4-aminophenyl)benzothiazolyl)-2-oxoethyl)-1,4, 7-triazacyclononane (L4). The ligands have been applied in the synthesis of a series of copper (II) complexes, [Cu(L1)(OH2)](ClO4) 2·0.5ACN (C1), [Cu(L3)](ClO4)2· ACN (C2) and [Cu(L4)(OH2)](ClO4)2·0.5THF (C4) whose structures have been determined by X-ray crystallography. As commonly observed for Cu(II) complexes of 1,4,7-triazacyclononane derivatives, the geometry of the metal centre ranges from distorted square pyramidal to pseudo-octahedral. Notably, the amide carbonyl coordinates to the copper(II) centre in C1 and C2 but not in C4 where the presence of an additional pyridyl group results in an N5 coordination sphere.